Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers

William N. Rom, Judith D. Goldberg, Doreen Addrizzo-Harris, Heather N. Watson, Michael Khilkin, Alissa K. Greenberg, David P. Naidich, Bernard Crawford, Ellen Eylers, Daorong Liu, Eng M. Tan

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Sera from lung cancer patients contain autoantibodies that react with tumor associated antigens (TAAs) that reflect genetic over-expression, mutation, or other anomalies of cell cycle, growth, signaling, and metabolism pathways.Methods: We performed immunoassays to detect autoantibodies to ten tumor associated antigens (TAAs) selected on the basis of previous studies showing that they had preferential specificity for certain cancers. Sera examined were from lung cancer patients (22); smokers with ground-glass opacities (GGOs) (46), benign solid nodules (55), or normal CTs (35); and normal non-smokers (36). Logistic regression models based on the antibody biomarker levels among the high risk and lung cancer groups were developed to identify the combinations of biomarkers that predict lung cancer in these cohorts.Results: Statistically significant differences in the distributions of each of the biomarkers were identified among all five groups. Using Receiver Operating Characteristic (ROC) curves based on age, c-myc, Cyclin A, Cyclin B1, Cyclin D1, CDK2, and survivin, we obtained a sensitivity = 81% and specificity = 97% for the classification of cancer vs smokers(no nodules, solid nodules, or GGO) and correctly predicted 31/36 healthy controls as noncancer.Conclusion: A pattern of autoantibody reactivity to TAAs may distinguish patients with lung cancer versus smokers with normal CTs, stable solid nodules, ground glass opacities, or normal healthy never smokers.

Original languageEnglish (US)
Article number234
JournalBMC Cancer
Volume10
DOIs
StatePublished - May 26 2010
Externally publishedYes

Fingerprint

Autoantibodies
Lung Neoplasms
Neoplasm Antigens
Glass
Biomarkers
Logistic Models
Cyclin B1
Cyclin A
Cyclin D1
Serum
Immunoassay
ROC Curve
Neoplasms
Cell Cycle
Sensitivity and Specificity
Mutation
Antibodies
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Rom, W. N., Goldberg, J. D., Addrizzo-Harris, D., Watson, H. N., Khilkin, M., Greenberg, A. K., ... Tan, E. M. (2010). Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer, 10, [234]. https://doi.org/10.1186/1471-2407-10-234

Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. / Rom, William N.; Goldberg, Judith D.; Addrizzo-Harris, Doreen; Watson, Heather N.; Khilkin, Michael; Greenberg, Alissa K.; Naidich, David P.; Crawford, Bernard; Eylers, Ellen; Liu, Daorong; Tan, Eng M.

In: BMC Cancer, Vol. 10, 234, 26.05.2010.

Research output: Contribution to journalArticle

Rom, WN, Goldberg, JD, Addrizzo-Harris, D, Watson, HN, Khilkin, M, Greenberg, AK, Naidich, DP, Crawford, B, Eylers, E, Liu, D & Tan, EM 2010, 'Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers', BMC Cancer, vol. 10, 234. https://doi.org/10.1186/1471-2407-10-234
Rom, William N. ; Goldberg, Judith D. ; Addrizzo-Harris, Doreen ; Watson, Heather N. ; Khilkin, Michael ; Greenberg, Alissa K. ; Naidich, David P. ; Crawford, Bernard ; Eylers, Ellen ; Liu, Daorong ; Tan, Eng M. / Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. In: BMC Cancer. 2010 ; Vol. 10.
@article{7beab69c637f43e18a8f5bad0cbd991f,
title = "Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers",
abstract = "Background: Sera from lung cancer patients contain autoantibodies that react with tumor associated antigens (TAAs) that reflect genetic over-expression, mutation, or other anomalies of cell cycle, growth, signaling, and metabolism pathways.Methods: We performed immunoassays to detect autoantibodies to ten tumor associated antigens (TAAs) selected on the basis of previous studies showing that they had preferential specificity for certain cancers. Sera examined were from lung cancer patients (22); smokers with ground-glass opacities (GGOs) (46), benign solid nodules (55), or normal CTs (35); and normal non-smokers (36). Logistic regression models based on the antibody biomarker levels among the high risk and lung cancer groups were developed to identify the combinations of biomarkers that predict lung cancer in these cohorts.Results: Statistically significant differences in the distributions of each of the biomarkers were identified among all five groups. Using Receiver Operating Characteristic (ROC) curves based on age, c-myc, Cyclin A, Cyclin B1, Cyclin D1, CDK2, and survivin, we obtained a sensitivity = 81{\%} and specificity = 97{\%} for the classification of cancer vs smokers(no nodules, solid nodules, or GGO) and correctly predicted 31/36 healthy controls as noncancer.Conclusion: A pattern of autoantibody reactivity to TAAs may distinguish patients with lung cancer versus smokers with normal CTs, stable solid nodules, ground glass opacities, or normal healthy never smokers.",
author = "Rom, {William N.} and Goldberg, {Judith D.} and Doreen Addrizzo-Harris and Watson, {Heather N.} and Michael Khilkin and Greenberg, {Alissa K.} and Naidich, {David P.} and Bernard Crawford and Ellen Eylers and Daorong Liu and Tan, {Eng M.}",
year = "2010",
month = "5",
day = "26",
doi = "10.1186/1471-2407-10-234",
language = "English (US)",
volume = "10",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers

AU - Rom, William N.

AU - Goldberg, Judith D.

AU - Addrizzo-Harris, Doreen

AU - Watson, Heather N.

AU - Khilkin, Michael

AU - Greenberg, Alissa K.

AU - Naidich, David P.

AU - Crawford, Bernard

AU - Eylers, Ellen

AU - Liu, Daorong

AU - Tan, Eng M.

PY - 2010/5/26

Y1 - 2010/5/26

N2 - Background: Sera from lung cancer patients contain autoantibodies that react with tumor associated antigens (TAAs) that reflect genetic over-expression, mutation, or other anomalies of cell cycle, growth, signaling, and metabolism pathways.Methods: We performed immunoassays to detect autoantibodies to ten tumor associated antigens (TAAs) selected on the basis of previous studies showing that they had preferential specificity for certain cancers. Sera examined were from lung cancer patients (22); smokers with ground-glass opacities (GGOs) (46), benign solid nodules (55), or normal CTs (35); and normal non-smokers (36). Logistic regression models based on the antibody biomarker levels among the high risk and lung cancer groups were developed to identify the combinations of biomarkers that predict lung cancer in these cohorts.Results: Statistically significant differences in the distributions of each of the biomarkers were identified among all five groups. Using Receiver Operating Characteristic (ROC) curves based on age, c-myc, Cyclin A, Cyclin B1, Cyclin D1, CDK2, and survivin, we obtained a sensitivity = 81% and specificity = 97% for the classification of cancer vs smokers(no nodules, solid nodules, or GGO) and correctly predicted 31/36 healthy controls as noncancer.Conclusion: A pattern of autoantibody reactivity to TAAs may distinguish patients with lung cancer versus smokers with normal CTs, stable solid nodules, ground glass opacities, or normal healthy never smokers.

AB - Background: Sera from lung cancer patients contain autoantibodies that react with tumor associated antigens (TAAs) that reflect genetic over-expression, mutation, or other anomalies of cell cycle, growth, signaling, and metabolism pathways.Methods: We performed immunoassays to detect autoantibodies to ten tumor associated antigens (TAAs) selected on the basis of previous studies showing that they had preferential specificity for certain cancers. Sera examined were from lung cancer patients (22); smokers with ground-glass opacities (GGOs) (46), benign solid nodules (55), or normal CTs (35); and normal non-smokers (36). Logistic regression models based on the antibody biomarker levels among the high risk and lung cancer groups were developed to identify the combinations of biomarkers that predict lung cancer in these cohorts.Results: Statistically significant differences in the distributions of each of the biomarkers were identified among all five groups. Using Receiver Operating Characteristic (ROC) curves based on age, c-myc, Cyclin A, Cyclin B1, Cyclin D1, CDK2, and survivin, we obtained a sensitivity = 81% and specificity = 97% for the classification of cancer vs smokers(no nodules, solid nodules, or GGO) and correctly predicted 31/36 healthy controls as noncancer.Conclusion: A pattern of autoantibody reactivity to TAAs may distinguish patients with lung cancer versus smokers with normal CTs, stable solid nodules, ground glass opacities, or normal healthy never smokers.

UR - http://www.scopus.com/inward/record.url?scp=77952646004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952646004&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-10-234

DO - 10.1186/1471-2407-10-234

M3 - Article

C2 - 20504322

AN - SCOPUS:77952646004

VL - 10

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 234

ER -